TX-SNOW-SOFTWARE
16.11.2023 15:01:58 CET | Business Wire | Press release
Snow Software, the global leader in technology intelligence, today previewed Snow Copilot, the first-in-a-series of Artificial Intelligence (AI) capabilities designed to solve large challenges in IT Asset Management (ITAM) and FinOps. Developed in its innovation incubator Snow Labs, Snow Copilot is an AI assistant that empowers users to ask conversational questions and receive natural language responses. At release, Snow Copilot is available for Software Asset Management (SAM) computer data in Snow Atlas with more use cases being explored over time.
Snow Labs is a multiprong innovation initiative to help organizations make better decisions and deliver positive business outcomes with Technology Intelligence, or the ability to understand and manage all technology data, via Snow Atlas. The current project focuses on using artificial intelligence to advance data insights and further explore ways to tackle multifaceted ITAM and FinOps challenges, the first offering powered by Snow AI.
“We created Snow Labs as a space for rapid experimentation and prototyping, allowing us to test emerging technologies that sat outside of our standard product roadmap,” said Steve Tait, Chief Technology Officer and EVP, Research and Development at Snow. “Artificial intelligence is a great example of a rapidly evolving, emerging technology that could allow Snow Labs to address a myriad of challenges our customers face when making sense of their technology asset data. We believe that AI will fundamentally transform the way our customers and partners interact with their data. This is just one of many ways we are working to bring our vision around Technology Intelligence to life through innovation.”
Enhancing the Value of Data with Snow
IT manages vast amounts of data but struggles to turn that data into actionable intelligence for business impact. According to a recent Snow report, 91% of IT leaders said they need to invest in tools to extract more value out of their data. This is a contributing factor in the growing visibility gap between IT and the business units they support. IT struggles to know what software and cloud services are running both within IT and across the enterprise leading to technology overspend, higher security and compliance risk, reduced ITSM data quality, and slower decision-making. Generative AI provides new toolsets for Snow to tackle the visibility gap when it comes to understanding and acting on large technology asset data sets for ITAM, SaaS management, and FinOps.
Snow Copilot, one of the first AI assistants developed to solve advanced challenges for ITAM and FinOps, leverages the Microsoft Azure OpenAI Service. It allows customers to input questions and receive insights on their computer data, such as “How many computers have been installed in the last 90 days?,” as well as explore “what if” scenarios all directly within Snow Atlas. Snow Copilot reduces the need to export data into PowerBI or Excel to get insights into advanced questions on forecasting, asset allocation, and trend identification of SAM computer data. All data remains secure in the customer environment ensuring data privacy and integrity.
Additional AI-enabled features within the Snow AI umbrella are under exploration for 2024, including:
- Machine Learning Entitlement Ingestion: Eliminate manual, costly entitlement uploads with automated invoice processing powered by machine learning.
- Enhanced Data Intelligence Service (DIS) dataset with OpenAI: Receive more context about the SaaS applications running in your organization with enhanced descriptions including richer details on categories, function, etc. from the Snow DIS normalization and augmentation service.
- Fine-tuning Large Language Models (LLM) on Snow proprietary data: Make more informed and complex decisions on technology assets with personalized licensing recommendations.
These new AI capabilities will be available on Snow Atlas, the company’s Technology Intelligence platform. The platform, released in 2021, provides a more flexible and scalable foundation for continuous innovation. Snow Atlas allows organizations to bring together their ITAM, SaaS management, cloud cost and FinOps functions, providing a unified view and actionable intelligence to manage the entire IT landscape.
“The pace at which we can innovate on Snow Atlas, both in our standard product development cycles and through Snow Labs, is remarkable with more than one production release every day for the last three quarters,” said Tait. “We are entering a new era which will redefine how we work with technology, and we want to ensure organizations feel confident and prepared to embrace this monumental shift.”
Snow Copilot and other AI innovations will be available for current Snow Atlas customers who apply for the beta program. To learn more about Snow Labs and its innovation agenda, read CTO Steve Tait’s latest blog or to discover more on Snow Atlas, visit: https://www.snowsoftware.com/products/snow-atlas/.
About Snow Software
Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116093425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
